Poster Presentations 2019
DOI: 10.1136/annrheumdis-2019-eular.1460
|View full text |Cite
|
Sign up to set email alerts
|

Fri0109 effectiveness and Safety of Infliximab, Golimumab and Golimumab-Iv in Rheumatoid Arthritis Patients From a Prospective Observational Registry

Abstract: BackgroundLong-term registries are essential to evaluate new therapies in a patient population that differs from clinical trials and usually varies over time.ObjectivesTo describe the profile of rheumatoid arthritis (RA) patients treated with infliximab (IFX), golimumab subcutaneous (GLM) or intravenous (GLM-IV) in Canadian routine care, along with its effectiveness and safety.Methods1577 RA patients treated with IFX, GLM or GLM-IV were enrolled into the Biologic Treatment Registry Across Canada (BioTRAC) betw… Show more

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles